HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shusen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai‐Min Hui, Binghe XuNature Communications 2024 · DOI

Abstract

Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 trial (NCT03944499), patients with HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) with a 3 + 3 design in phase 1a; patients with metastatic HER2-positive BC received FS-1502 at the recommended phase 2 dose (RP2D) in phase 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and RP2D for phase 1a and objective response rate (ORR) for phase 1b. A total of 150 patients with HER2-expressing solid tumors (n = 5) and BC (n = 145) were enrolled (female, n = 146, 97.3%). One DLT each was reported at 3.0 and 3.5 mg/kg; the MTD was not reached. The RP2D was 2.3 mg/kg once every 3 weeks. Five (3.3%) patients experienced pneumonitis; four (2.7%) had grade 3 reversible ocular events. Of 67 HER2-positive BC patients receiving the RP2D, the best ORR was 53.7% (95% CI, 41.1-66.0%), including PRs confirmed (confirmed ORR, 37.5%) and pending for confirmation. FS-1502 was well tolerated with limited ocular and pulmonary findings and demonstrated promising antitumor activity in HER2-positive BC patients.

Introduction

The advent of HER2-targeting antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) has significantly improved outcomes for patients with HER2-positive metastatic breast cancer (mBC). However, these agents are often associated with serious toxicities, such as interstitial lung disease (ILD)/pneumonitis, ocular issues, and gastrointestinal distress. Furthermore, resistance eventually limits their long-term efficacy. There is a clear clinical need for next-generation ADCs that utilize improved linker technologies and payloads to enhance the therapeutic window—maximizing tumor-killing efficacy while minimizing off-target damage to healthy tissues.

Methods

This multicenter, open-label Phase 1 trial evaluated FS-1502, a novel HER2-targeting ADC. FS-1502 is engineered with site-specific chemoenzymatic conjugation to ensure a homogeneous drug-to-antibody ratio (DAR). It features a cleavable $\beta$-glucuronide linker, designed to remain stable in systemic circulation but undergo rapid enzymatic cleavage by $\beta$-glucuronidase, which is highly expressed in the tumor microenvironment. The payload is monomethyl auristatin F (MMAF), a potent antimitotic agent.

Study Design

The trial was divided into two phases:

  • Phase 1a (Dose Escalation): Used a "3 + 3" design to evaluate safety across doses ranging from 0.1 mg/kg to 3.5 mg/kg, aiming to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
  • Phase 1b (Dose Expansion): Assessed the efficacy and safety of the RP2D in a larger cohort of patients with HER2-positive mBC.
Patient disposition and dose cohorts across Phase 1a and 1b.

Patient Population

A total of 150 patients were enrolled (145 with breast cancer, 5 with other HER2-expressing solid tumors). The population was heavily pre-treated, with 88.7% of patients having received a median of three prior lines of therapy, including trastuzumab and pyrotinib.

Results

Safety and Tolerability

The MTD was not reached, and the RP2D was established at 2.3 mg/kg administered once every three weeks (Q3W). FS-1502 demonstrated a manageable safety profile. Notably, the incidence of severe pulmonary and ocular toxicities was low: only 3.3% of patients experienced pneumonitis, and grade 3 ocular events occurred in only 2.7% of patients and were reversible. Pharmacokinetic data indicated that the site-specific conjugation and stable linker resulted in very low levels of free-circulating MMAF, which likely accounts for the reduced systemic side effects.

Antitumor Activity

Among the 67 patients with HER2-positive mBC treated at the RP2D, FS-1502 showed robust antitumor activity. The best objective response rate (ORR) was 53.7% (confirmed ORR: 37.5%), and the disease control rate (DCR) was 88.1%. The median progression-free survival (PFS) was 15.5 months.

Clinical activity of FS-1502 at the RP2D, including duration of response (A), best percentage change in tumor size (B), and progression-free survival (C).

Activity was also noted in patients with HER2-low expression (ORR 26.7%), suggesting that FS-1502 may have utility beyond the strictly HER2-positive population.

Discussion and Conclusion

FS-1502 demonstrates promising efficacy and a differentiated safety profile in heavily pre-treated HER2-positive mBC. Its unique site-specific conjugation and $\beta$-glucuronide linker technology appear to mitigate some of the "Achilles' heels" of earlier ADCs, particularly regarding pulmonary and ocular toxicities. While these Phase 1 results are encouraging, the single-arm design and small subgroup sizes necessitate further validation. A randomized Phase 3 trial is currently underway comparing FS-1502 directly against T-DM1 to definitively establish its place in the treatment paradigm.

Summary updated

Abstract

Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 trial (NCT03944499), patients with HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) with a 3 + 3 design in phase 1a; patients with metastatic HER2-positive BC received FS-1502 at the recommended phase 2 dose (RP2D) in phase 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and RP2D for phase 1a and objective response rate (ORR) for phase 1b. A total of 150 patients with HER2-expressing solid tumors (n = 5) and BC (n = 145) were enrolled (female, n = 146, 97.3%). One DLT each was reported at 3.0 and 3.5 mg/kg; the MTD was not reached. The RP2D was 2.3 mg/kg once every 3 weeks. Five (3.3%) patients experienced pneumonitis; four (2.7%) had grade 3 reversible ocular events. Of 67 HER2-positive BC patients receiving the RP2D, the best ORR was 53.7% (95% CI, 41.1-66.0%), including PRs confirmed (confirmed ORR, 37.5%) and pending for confirmation. FS-1502 was well tolerated with limited ocular and pulmonary findings and demonstrated promising antitumor activity in HER2-positive BC patients.
BibTeX
@inproceedings{li2024her,
  author = {Qiao Li and Ying Cheng and Zhongsheng Tong and Yunjiang Liu and Xian Wang and Min Yan and Jianhua Chang and Shusen Wang and Caiwen Du and Liang Li and Chunjiao Wu and Mingxia Wang and Zhuo Wang and Zhuli Wu and Xingli Wang and Yongli Jin and Lei Diao and Yi Sun and Yongjiao Zhang and Ai‐Min Hui and Binghe Xu},
  title = {{HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial}},
  booktitle = {Nature Communications},
  year = {2024},
  doi = {10.1038/s41467-024-48798-w},
}
Figure